BMS-229724

• Description:

  BMS-229724 is an orally active and tight-binding cytosolic phospholipase A2 (cPLA2) inhibitor with an IC50 of 2.8 μM. BMS-229724 can inhibit the production of arachidonic acid and eicosanoids in U937 cells, neutrophils, platelets, and other cells. BMS-229724 has anti-inflammatory activity and can be used in the research of diseases such as skin inflammation[1][2].

• UNSPSC:

  12352005

• Target:

  Phospholipase

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C (CCC1=CC=C (OCCS (=O) (CCOC (C2=CC=C (Cl) C=C2) C3=CC=C (Cl) C=C3) =O) C=C1) C (F) (F) F

• Molecular Formula:

  C27H25Cl2F3O5S

• Molecular Weight:

  589.45

• References & Citations:

  [1]Magrioti V, et al. Synthetic inhibitors of group IVA and group VIA phospholipase A2[J]. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistryrrent Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents), 2006, 5 (2) : 189-203.|[2]Burke JR, et al. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J Pharmacol Exp Ther. 2001 Jul;298 (1) :376-85.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Phospholipase A

• CAS Number:

  221914-85-8